Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stratec SESRBZF 67 5-Year Yield-on-Cost % is 0.00 as of Jul. 31, 2026. GuruFocus rates SRBZF with a GF Score™ of 67/100 and a GF Value™ of $120.28. The stock has 5 warning signs investors should review. Among 319 Medical Devices & Instruments companies, Stratec SE ranks worse than 57.37% on this metric.
Stratec SE's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Stratec SE's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Stratec SE's highest Yield on Cost was 2.28. The lowest was 0.00. And the median was 0.84.
SRBZF's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.45 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Stratec SE (OTCPK:SRBZF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Stratec SE 5-Year Yield-on-Cost % Related Terms
SRBZF vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Stratec SE's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stratec SE 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stratec SE's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Stratec SE's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Stratec SE is calculated as
Stratec SE (SRBZF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Stratec SE and its competitors. According to the industry distribution chart, Stratec SE ranks #183 out of 319 companies in the Medical Devices & Instruments industry, placing it in the top 57.4%.
Is Stratec SE's 5-Year Yield-on-Cost % too high?
Stratec SE's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Stratec SE ranks #183 out of 319 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Stratec SE has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Stratec SE's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Stratec SE ranks #183 out of 319 companies for 5-Year Yield-on-Cost %. This places Stratec SE in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.45, based on 319 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Stratec SE and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stratec SE's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stratec SE stock overvalued right now?
Stratec SE (SRBZF) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is $120.28, compared to a current price of $72.96 — trading 39.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Stratec SE's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Stratec SE (SRBZF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stratec SE (SRBZF) Overvalued in 2026?
Based on GuruFocus' analysis, Stratec SE stock appears to be undervalued.
The current stock price of $72.96 is trading 39.3% below its estimated GF Value™ of $120.28.
Key valuation signals for SRBZF:
5-Year Yield-on-Cost %: 0.00
GF Value™: $120.28 vs. price of $72.96 (39.3% below fair value)
No single metric tells the full story. See the SRBZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stratec SE designs and manufactures automation solutions for regulated laboratory markets. STRATEC acts as an OEM partner to players in the in-vitro diagnostics and life sciences markets. The Group's product range includes both hardware solutions, software solutions, and related consumables, as well as independently marketed consumables. These products are mostly combined into fully integrated system solutions and often receive market approval together with partners' reagents.
67GF Score
Get the complete analysis for SRBZF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRBZF has been successfully added to your 
